Psychopharmacology Practice Questions

Q: A female patient on lithium for bipolar disorder for 6 months presents with seizures, tremors, confusion, and weakness. What is the primary investigation to diagnose lithium toxicity?

serum lithium level. ***Serum lithium level*** - An elevated **serum lithium level** is the definitive diagnostic test for lithium toxicity, directly measuring the concentration of the drug in the patient's blood. - The symptoms of seizures, tremors, confusion, and weakness are all classic signs of **lithium neurotoxicity**, making the measurement of its blood concentration critical. - Therapeutic range: 0.6-1.2 mEq/L; toxicity typically occurs at levels >1.5 mEq/L. *Serum electrolytes* - While lithium toxicity can affect **electrolyte balance** (e.g., causing hyponatremia due to renal effects), measuring electrolytes alone is not sufficient to diagnose lithium toxicity. - Electrolytes should be checked as **dehydration and hyponatremia can precipitate toxicity**, but they don't directly measure lithium concentration. - Changes in electrolytes are often secondary and not directly indicative of the circulating **lithium concentration**. *ECG* - An **ECG** can reveal cardiac effects of lithium toxicity, such as **T-wave inversions** or **QT prolongation**, but it does not directly measure lithium levels or confirm the diagnosis. - Cardiac abnormalities are usually seen in severe toxicity and are not the primary diagnostic marker. - ECG is important for monitoring cardiac complications but is not diagnostic of lithium toxicity itself. *MRI* - An **MRI of the brain** might be considered in cases of severe neurological symptoms like seizures or altered mental status to rule out other causes or assess for **cerebral edema**, but it does not diagnose lithium toxicity itself. - It is a supportive or exclusionary test, not the primary diagnostic tool for lithium overdose.

Q: What is the classical drug of choice for Tourette syndrome?

Haloperidol. ***Haloperidol*** - **Haloperidol**, a **first-generation antipsychotic**, is highly effective in blocking dopamine receptors and reducing the frequency and severity of tics in Tourette syndrome. - Its efficacy in managing severe tics makes it a **classical drug of choice**, particularly for individuals who do not respond to less potent interventions. *Amantadine* - **Amantadine** is primarily used as an **antiviral agent** against influenza A and as an antiparkinsonian drug, enhancing dopamine release. - It is not indicated for the treatment of Tourette syndrome as its mechanism of action is related to increasing dopamine, which would worsen tics. *Propranolol* - **Propranolol** is a **beta-blocker** primarily used to treat conditions like hypertension, angina, and essential tremor by reducing adrenergic activity. - While it can help with anxiety and some motor symptoms in specific conditions, it is not a primary treatment for the motor and vocal tics characteristic of Tourette syndrome. *Diazepam* - **Diazepam** is a **benzodiazepine** that acts as a central nervous system depressant, used primarily for anxiety, insomnia, and muscle spasms. - While it can help with associated anxiety, it does not directly address the underlying mechanism of tics in Tourette syndrome and is not a drug of choice for tic management.

Q: What is the treatment of choice for akathisia?

Propranolol. ***Propranolol*** - **Beta-blockers** like propranolol are considered first-line treatment for akathisia due to their ability to reduce central as well as peripheral noradrenergic hyperactivity and anxiety. - They are particularly effective in alleviating the subjective feeling of **inner restlessness** and the objective motor symptoms, especially when the akathisia is induced by antipsychotics. *Benztropine* - This is an **anticholinergic** medication primarily used to treat other extrapyramidal symptoms like **dystonia** and **pseudoparkinsonism**. - While it might provide some relief for certain motor aspects, it is generally less effective for the subjective feeling of restlessness in akathisia and can have significant side effects. *Dantrolene* - **Dantrolene** is a direct-acting **skeletal muscle relaxant** used primarily in the treatment of **neuroleptic malignant syndrome (NMS)** and malignant hyperthermia. - It is not indicated for the management of extrapyramidal symptoms like akathisia. *Lithium* - **Lithium** is a mood stabilizer used predominantly in the treatment of **bipolar disorder**. - It has no role in the direct treatment of akathisia; however, it can ironically sometimes induce or worsen akathisia as a side effect itself.

Q: What is the drug of choice (DOC) for a schizophrenic patient with poor oral absorption?

Fluphenazine. ***Fluphenazine*** - **Fluphenazine** is available as a **long-acting injectable** (LAI) formulation, specifically **fluphenazine decanoate**, making it an ideal choice for patients with **poor oral absorption** or adherence issues. - Its **depot injection** bypasses the need for oral intake, ensuring therapeutic drug levels are maintained over several weeks. *Clozapine* - **Clozapine** is an **oral antipsychotic** and requires consistent oral intake for efficacy. - It is often reserved for **treatment-resistant schizophrenia** and is not available in a long-acting injectable form suitable for poor oral absorption. *Sulpride* - **Sulpride** is primarily an **oral antipsychotic** and its administration relies on adequate oral absorption. - It is not available in a formulation that would circumvent issues of poor oral absorption. *Penfluridol* - **Penfluridol** is an **oral long-acting antipsychotic**, but it still requires oral administration. - While long-acting, its efficacy depends on the patient's ability to absorb the drug orally, which is compromised in this scenario.

Q: What is a therapeutic indication for the use of liothyronine?

Resistant depression. ***Resistant depression*** - Liothyronine (T3) can be used as an **adjunctive therapy** for patients with major depressive disorder who have not responded adequately to antidepressant monotherapy. - While the exact mechanism is not fully understood, it's thought to improve antidepressant response by modulating **neurotransmitter systems** and receptor sensitivity in the brain. *Social phobia* - **Social phobia**, or social anxiety disorder, is primarily treated with psychotherapy (e.g., CBT) and medications like **SSRIs** or **SNRIs**. - Liothyronine is **not a primary or adjunctive treatment** for social phobia. *Alzheimer's disease* - **Alzheimer's disease** is a neurodegenerative disorder treated with cholinesterase inhibitors (e.g., donepezil) and NMDA receptor antagonists (e.g., memantine). - There is currently **no established role for liothyronine** in the treatment of Alzheimer's disease. *Cataplexy* - **Cataplexy**, a symptom of narcolepsy, is characterized by sudden muscle weakness triggered by strong emotions. - It is typically managed with medications like **sodium oxybate** or certain antidepressants (e.g., venlafaxine), not liothyronine.

Q: Which FDA approved drug is used for refractory schizophrenia?

Clozapine. ***Clozapine*** - **Clozapine** is an **atypical antipsychotic** uniquely approved for the treatment of **refractory schizophrenia**, where other antipsychotics have failed. - Its efficacy in treatment-resistant cases is attributed to its complex pharmacological profile, including antagonism of multiple **dopamine** and **serotonin receptors**. *Amoxapine* - **Amoxapine** is a **tetracyclic antidepressant** with some antipsychotic properties due to **dopamine receptor blockade**, but it is not a first-line or approved treatment for refractory schizophrenia. - It's primarily used for **major depressive disorder** and carries a risk of inducing **extrapyramidal symptoms**. *Haloperidol* - **Haloperidol** is a **first-generation (typical) antipsychotic** effective in treating acute psychotic symptoms but generally not used as the agent of choice for **refractory schizophrenia**. - Its primary mechanism involves potent **D2 dopamine receptor blockade**, which often leads to significant **extrapyramidal side effects**. *Penfluridol* - **Penfluridol** is a **long-acting, first-generation antipsychotic** that is used for maintenance treatment of schizophrenia, but it is not specifically indicated or uniquely effective for **refractory cases**. - It has a prolonged duration of action, making it suitable for patients requiring less frequent dosing to improve **medication adherence**.

Q: Which of the following was the PRIMARY indication for which venlafaxine was first FDA approved?

Major depressive disorder. ***Major depressive disorder***- Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) [1], and its primary FDA approval was for the treatment of major depressive disorder [1]- Its mechanism of action, increasing the availability of serotonin and norepinephrine in the brain, is highly effective for managing symptoms of depression [2]- It was first approved by the FDA in 1993 specifically for this indication*Attention deficit hyperactivity disorder (ADHD)*- While some antidepressants are used off-label for ADHD, particularly norepinephrine-reuptake inhibitors like atomoxetine, venlafaxine was not primarily approved for this condition- The mainstays for ADHD treatment are typically stimulants (e.g., methylphenidate, amphetamine) or non-stimulants like atomoxetine*Bipolar disorder*- Venlafaxine can be used as an adjunct in treating the depressive phase of bipolar disorder, but it is not indicated as a monotherapy due to the risk of inducing mania or hypomania- The primary medications for bipolar disorder are mood stabilizers (e.g., lithium, valproate) and atypical antipsychotics*Schizophrenia*- Venlafaxine has no role in the primary treatment of schizophrenia, which is a psychotic disorder- The first-line treatment for schizophrenia involves antipsychotic medications that primarily target dopamine and serotonin receptors

Q: Which of the following is the preferred first-line pharmacological treatment for tardive dyskinesia?

Valbenazine. ***Valbenazine*** - **Valbenazine** is a **VMAT2 inhibitor** approved by the FDA as a **first-line treatment** for tardive dyskinesia. - It works by reducing **presynaptic dopamine release**, thereby mitigating involuntary movements. - Along with deutetrabenazine, it represents the **preferred pharmacological approach** for tardive dyskinesia, with good efficacy and tolerability. *Tetrabenazine* - **Tetrabenazine** is also a **VMAT2 inhibitor** that reduces dopamine levels. - However, the **newer VMAT2 inhibitors** (valbenazine and deutetrabenazine) are generally **preferred as first-line** due to **better tolerability** (lower risk of depression, parkinsonism, and somnolence) and simpler dosing schedules. - Tetrabenazine may still be used when newer agents are unavailable. *Baclofen* - **Baclofen** is a **GABA-B receptor agonist** primarily used for spasticity and muscle rigidity. - While it has been explored for tardive dyskinesia, it is **not considered first-line** pharmacological treatment due to **limited efficacy** compared to VMAT2 inhibitors. *Cessation of antipsychotic medication* - While sometimes considered, outright **cessation** of antipsychotic medication is often **not feasible** or desirable due to the risk of **relapse of underlying psychiatric illness**. - It can sometimes even **worsen tardive dyskinesia symptoms** temporarily (withdrawal-emergent dyskinesia). - The first-line approach involves **pharmacological treatment with VMAT2 inhibitors** to manage the dyskinesia while maintaining psychiatric stability.

Q: What is the condition for which lithium is considered the treatment of choice?

Bipolar Disorder prophylaxis. ***Bipolar Disorder prophylaxis*** - Lithium is a **mood stabilizer** highly effective in preventing both manic and depressive episodes in patients with **bipolar disorder**. - Its long-term use significantly reduces the frequency and severity of relapses, thereby improving the **quality of life** for these patients. *Schizophrenia* - **Antipsychotic medications** are the primary treatment for schizophrenia, targeting positive and negative symptoms. - Lithium is not considered a first-line treatment for schizophrenia and is generally not effective in managing its core symptoms like **psychosis** and **thought disorganization**. *Acute mania management* - While lithium can be used to treat **acute mania**, it often has a slower onset of action compared to other agents like **antipsychotics** or **valproate**, which are often preferred for rapid symptom control. - For immediate stabilization of acute mania, faster-acting medications are usually initiated, with lithium being added later for prophylaxis. *Unipolar Major Depressive Disorder prophylaxis* - The primary treatment for **unipolar major depressive disorder** involves **antidepressants**, psychotherapy, or a combination of both. - While lithium can be used as an augmentation strategy for refractory depression, it is not considered the treatment of choice for primary prophylaxis of unipolar depression.

Q: Psychotic patient on antipsychotic drugs develops torticollis within 4 days of therapy. What is the treatment?

Central anticholinergic drugs. ***Central anticholinergic drugs*** - The patient is experiencing an **acute dystonic reaction**, a common extrapyramidal side effect of antipsychotics, such as **torticollis**, which requires immediate treatment with central anticholinergic agents. - Medications like **benztropine** or **diphenhydramine** are indicated to quickly reverse these symptoms by blocking acetylcholine activity in the basal ganglia. *Peripheral anticholinergic drugs* - These agents primarily act outside the central nervous system and are not effective in treating centrally mediated extrapyramidal symptoms like **acute dystonia**. - Their main use is for conditions like **bradycardia** or to reduce **gastrointestinal motility**. *Beta blockers* - **Beta-blockers** are primarily used to treat **akathisia** (restlessness) associated with antipsychotic medication, not acute dystonic reactions like torticollis. - They work by reducing the somatic manifestations of anxiety and motor restlessness. *Dantrolene* - **Dantrolene** is a **direct skeletal muscle relaxant** primarily used in the treatment of **neuroleptic malignant syndrome** or **malignant hyperthermia**. - It is not the first-line treatment for acute dystonic reactions as it does not address the underlying neurochemical imbalance.

Question 1

A female patient on lithium for bipolar disorder for 6 months presents with seizures, tremors, confusion, and weakness. What is the primary investigation to diagnose lithium toxicity?

Accepted Answer

serum lithium level

Answer

serum electrolytes

Answer

ECG

Answer

MRI

Question 2

What is the classical drug of choice for Tourette syndrome?

Accepted Answer

Haloperidol

Answer

Amantadine

Answer

Propranolol

Answer

Diazepam

Question 3

What is the treatment of choice for akathisia?

Accepted Answer

Propranolol

Answer

Benztropine

Answer

Dantrolene

Answer

Lithium

Question 4

What is the drug of choice (DOC) for a schizophrenic patient with poor oral absorption?

Accepted Answer

Fluphenazine

Answer

Clozapine

Answer

Sulpride

Answer

Penfluridol

Question 5

What is a therapeutic indication for the use of liothyronine?

Accepted Answer

Resistant depression

Answer

Social phobia

Answer

Cataplexy

Answer

Alzheimer's disease

Question 6

Which FDA approved drug is used for refractory schizophrenia?

Accepted Answer

Clozapine

Answer

Amoxapine

Answer

Haloperidol

Answer

Penfluridol

Question 7

Which of the following was the PRIMARY indication for which venlafaxine was first FDA approved?

Accepted Answer

Major depressive disorder

Answer

Bipolar disorder

Answer

Attention deficit hyperactivity disorder (ADHD)

Answer

Schizophrenia

Question 8

Which of the following is the preferred first-line pharmacological treatment for tardive dyskinesia?

Accepted Answer

Valbenazine

Answer

Tetrabenazine

Answer

Baclofen

Answer

Cessation of antipsychotic medication

Question 9

What is the condition for which lithium is considered the treatment of choice?

Accepted Answer

Bipolar Disorder prophylaxis

Answer

Schizophrenia

Answer

Acute mania management

Answer

Unipolar Major Depressive Disorder prophylaxis

Question 10

Psychotic patient on antipsychotic drugs develops torticollis within 4 days of therapy. What is the treatment?

Accepted Answer

Central anticholinergic drugs

Answer

Peripheral anticholinergic drugs

Answer

Beta blockers

Answer

Dantrolene

Psychopharmacology — MCQs

Psychopharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?